Title:
ワクチンおよび抗腫瘍ワクチンを調製する方法
Document Type and Number:
Japanese Patent JP2006516258
Kind Code:
A
Abstract:
The present invention provides a method of preparing a vaccine. Said method includes: 1) analyzing specific antigen of particular pathogen; 2) obtaining a polynucleotide encoding the specific antigen; 3) obtaining a polynucleotide sequence having a sufficient difference from the polynucleotide; 4) preparing a vaccine using the polynucleotide sequence. The present invention also provides anti-tumor vaccines, particularly anti-tumor EGFR molecular vaccines. Said anti-tumor EGFR molecular vaccines are a variety of new biotechnological vaccines constructed by using EGFR moleculars as anigens, including protein vaccines, gene vaccines, virus vaccines, gene-modified vaccines and stably transformed symbiotic bacterium. One of the biological function of the EGFR molecular vaccines has an anti-tumor effect on a variety of solid tumor cancer which over-express the EGFR molecular, eg., lung cancer, breast cancer, ovary cancer, colon cancer, prostate cancer, stomach cancer, etc, including a protective anti-tumor immune effect, therapeutic anti-tumor effect and inhibiting cancer metastasis. The anti-tumor action mechanism of EGFR molecular vaccine is that said EGFR moleculars may destroy an individual's immune tolerance to self-EGFR molecular as cross-reactive antigens, and therefore induce an immuno-cross-response to the self-EGFR molecular in the individual, including active immune reaction (cellular immune reaction and humoral immune reaction) and passive immune reaction (adoptive immune reaction). Said anti-tumor EGFR molecular vaccines are either traditional preparation (aqua, lyophilized powder) or nano preparation prepared by nano biotechnology. Said EGFR molecular vaccine exhibits an enhanced anti-tumor effect through the synergistic action of other immunopotentiator.
Inventors:
Tian, Lin
Way, Yuchuan
Way, Yuchuan
Application Number:
JP2004567232A
Publication Date:
June 29, 2006
Filing Date:
December 26, 2003
Export Citation:
Assignee:
Shen Jian Shi Ting Yu Yuan Shin
International Classes:
A61K39/00; A61K48/00; A61P35/00; C12N15/13; C07K14/71; C12N15/09
Domestic Patent References:
| JPH09511146A | 1997-11-11 | |||
| JP2002514573A | 2002-05-21 | |||
| JP2001506493A | 2001-05-22 |
Foreign References:
| WO2002083855A2 | 2002-10-24 |
Other References:
JPN6009062647, ＷＥＩ，Ｙ．Ｑ． ｅｔ ａｌ, "Ｉｍｍｕｎｏｇｅｎｅ ｔｈｅｒａｐｙ ｏｆ ｔｕｍｏｒｓ ｗｉｔｈ ｖａｃｃｉｎｅ ｂａｓｅｄ ｏｎ Ｘｅｎｏｐｕｓ ｈｏｍｏｌｏｇｏｕｓ ｖａｓｃｕｌａｒ ｅｎｄｏｔｈｅｌｉａｌ ｇｒｏｗｔｈ ｆａ", Ｐｒｏｃ Ｎａｔｌ Ａｃａｄ Ｓｃｉ Ｕ Ｓ Ａ, 2001, Ｖｏｌ．９８， Ｎｏ．２０, ｐ．１１５４５−５０
JPN6009062649, ＮＡＦＴＺＧＥＲ，Ｃ． ｅｔ ａｌ, "Ｉｍｍｕｎｅ ｒｅｓｐｏｎｓｅ ｔｏ ａ ｄｉｆｆｅｒｅｎｔｉａｔｉｏｎ ａｎｔｉｇｅｎ ｉｎｄｕｃｅｄ ｂｙ ａｌｔｅｒｅｄ ａｎｔｉｇｅｎ： ａ ｓｔｕｄｙ ｏｆ ｔｕｍｏｒ ｒｅｊｅｃｔｉｏｎ", Ｐｒｏｃ Ｎａｔｌ Ａｃａｄ Ｓｃｉ Ｕ Ｓ Ａ, 1996, Ｖｏｌ．９３， Ｎｏ．２５, ｐ．１４８０９−１４
JPN6009062649, ＮＡＦＴＺＧＥＲ，Ｃ． ｅｔ ａｌ, "Ｉｍｍｕｎｅ ｒｅｓｐｏｎｓｅ ｔｏ ａ ｄｉｆｆｅｒｅｎｔｉａｔｉｏｎ ａｎｔｉｇｅｎ ｉｎｄｕｃｅｄ ｂｙ ａｌｔｅｒｅｄ ａｎｔｉｇｅｎ： ａ ｓｔｕｄｙ ｏｆ ｔｕｍｏｒ ｒｅｊｅｃｔｉｏｎ", Ｐｒｏｃ Ｎａｔｌ Ａｃａｄ Ｓｃｉ Ｕ Ｓ Ａ, 1996, Ｖｏｌ．９３， Ｎｏ．２５, ｐ．１４８０９−１４
Attorney, Agent or Firm:
Takehiko Suzue
Satoshi Kono
Makoto Nakamura
Kurata Masatoshi
Takashi Mine
Yoshihiro Fukuhara
Toshio Shirane
Sadao Muramatsu
Nobuhisa Nogawa
Ryo Hashimoto
Tetsuya Kazama
Satoshi Kono
Makoto Nakamura
Kurata Masatoshi
Takashi Mine
Yoshihiro Fukuhara
Toshio Shirane
Sadao Muramatsu
Nobuhisa Nogawa
Ryo Hashimoto
Tetsuya Kazama